Stephen Hamshere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen Hamshere has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Anthony Mathur
Barts Heart Centre, Barts Health NHS Trust, London, UK
2 shared publications- Daniel A. Jones
Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London
2 shared publications Akhil Kapur
Department of Cardiology, Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
1 shared publicationAlex Byrne
Department of Cardiology, Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
1 shared publicationAlireza Yazdi
Barts Simulation and Education Department, St Bartholomew’s Hospital, London, UK
1 shared publicationAndreas Baumbach
Barts Heart Centre, Barts Health NHS Trust, London, UK
1 shared publication
Latest Publications
- Open Access
Simulation deficit in cardiology training: a missed opportunity for the modern trainee
Cardiology training today exists in a paradox. As the specialty becomes more complex, particularly in procedural domains, the time and resources available to train new cardiologists have dwindled. Simulation has become an increasingly important component of modern cardiology training, offering a safe, structured and reproducible environment in which clinical skills can be developed and refined.1 The term simulation encompasses a broad spectrum of educational approaches, ranging from focused task training to high-fidelity scenario-based learning. Task training is used to develop specific technical skills by breaking down complex procedures into their component parts—for example, practising lead manipulation and placement in permanent pacing using a haptic simulator, or employing biological models such as porcine tissue to gain proficiency in venous isolation and generator implantation. At the other end of the spectrum, high-fidelity simulation recreates real-world clinical environments, enabling trainees to manage cardiac arrest scenarios, respond to complications in a mock catheterisation laboratory and address challenges in team-based practice. Importantly, such high-fidelity approaches extend beyond technical competence, emphasising human factors, patient safety and team dynamics. Together, these modalities highlight the evolving role of simulation as a complementary tool that enhances traditional cath lab-based education and prepares trainees for the increasing complexity of contemporary cardiology practice.
Open AccessSimulation deficit in cardiology training: a missed opportunity for the modern trainee
Cardiology training today exists in a paradox. As the specialty becomes more complex, particularly in procedural domains, the time and resources available to train new cardiologists have dwindled. Simulation has become an increasingly important component of modern cardiology training, offering a safe, structured and reproducible environment in which clinical skills can be developed and refined.1 The term simulation encompasses a broad spectrum of educational approaches, ranging from focused task training to high-fidelity scenario-based learning. Task training is used to develop specific technical skills by breaking down complex procedures into their component parts—for example, practising lead manipulation and placement in permanent pacing using a haptic simulator, or employing biological models such as porcine tissue to gain proficiency in venous isolation and generator implantation. At the other end of the spectrum, high-fidelity simulation recreates real-world clinical environments, enabling trainees to manage cardiac arrest scenarios, respond to complications in a mock catheterisation laboratory and address challenges in team-based practice. Importantly, such high-fidelity approaches extend beyond technical competence, emphasising human factors, patient safety and team dynamics. Together, these modalities highlight the evolving role of simulation as a complementary tool that enhances traditional cath lab-based education and prepares trainees for the increasing complexity of contemporary cardiology practice.
- Open Access
- 10 March 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 42, 86-91
An Observational Study Assessing the Predictors of Procedural Failure From the Radial Approach: Is Right Radial Access Always the Best?
- 10 March 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 42, 86-91
Open AccessAn Observational Study Assessing the Predictors of Procedural Failure From the Radial Approach: Is Right Radial Access Always the Best?
- Open Access
- 20 April 2021
- Published by BMJ in Open Heart
- Vol. 8 (1) , e001446
Reintroduction of elective cardiac interventions in the era of COVID-19: the Barts experience
Background The response to COVID-19 has required cancellation of all but the most urgent procedures; there is therefore a need for the reintroduction of a safe elective pathway. Methods This was a study of a pilot pathway performed at Barts Heart Centre for the admission of patients requiring elective coronary and structural procedures during the COVID-19 pandemic (April–June 2020). All patients on coronary and structural waiting lists were screened for procedural indications, urgency and adverse features for COVID-19 prognosis and discussed at dedicated multidisciplinary teams. Dedicated admission pathways involving preadmission isolation, additional consent, COVID-19 PCR testing and dedicated clean areas were used. Results 143 patients (101 coronary and 42 structural) underwent procedures (coronary angiography, percutaneous coronary intervention, transcatheter aortic valve intervention and MitralClip) during the study period. The average age was 68.2; 74% were male; and over 93% had one or more moderate COVID-19 risk factors. All patients were COVID-19 PCR negative on admission with (8.1%) COVID-19 antibody positive (swab negative). All procedures were performed successfully with low rates of procedural complications (9.8%). At 2-week follow-up, no patients had symptoms or confirmed COVID-19 infection with significant improvements in quality if life and symptoms. Conclusion We demonstrated that patients undergoing coronary and structural procedures can be safely admitted during the COVID-19 pandemic, with no patients contracting COVID-19 during their admission. Reassuringly, patients reflective of typical practice, that is, those at moderate or higher risk, were treated successfully. This pilot provides important information applicable to other settings, specialties and areas to reintroduce services safely.
- 20 April 2021
- Published by BMJ in Open Heart
- Vol. 8 (1) , e001446
Open AccessReintroduction of elective cardiac interventions in the era of COVID-19: the Barts experience
Background The response to COVID-19 has required cancellation of all but the most urgent procedures; there is therefore a need for the reintroduction of a safe elective pathway. Methods This was a study of a pilot pathway performed at Barts Heart Centre for the admission of patients requiring elective coronary and structural procedures during the COVID-19 pandemic (April–June 2020). All patients on coronary and structural waiting lists were screened for procedural indications, urgency and adverse features for COVID-19 prognosis and discussed at dedicated multidisciplinary teams. Dedicated admission pathways involving preadmission isolation, additional consent, COVID-19 PCR testing and dedicated clean areas were used. Results 143 patients (101 coronary and 42 structural) underwent procedures (coronary angiography, percutaneous coronary intervention, transcatheter aortic valve intervention and MitralClip) during the study period. The average age was 68.2; 74% were male; and over 93% had one or more moderate COVID-19 risk factors. All patients were COVID-19 PCR negative on admission with (8.1%) COVID-19 antibody positive (swab negative). All procedures were performed successfully with low rates of procedural complications (9.8%). At 2-week follow-up, no patients had symptoms or confirmed COVID-19 infection with significant improvements in quality if life and symptoms. Conclusion We demonstrated that patients undergoing coronary and structural procedures can be safely admitted during the COVID-19 pandemic, with no patients contracting COVID-19 during their admission. Reassuringly, patients reflective of typical practice, that is, those at moderate or higher risk, were treated successfully. This pilot provides important information applicable to other settings, specialties and areas to reintroduce services safely.
- Open Access
- 5 April 2018
- Published by BMJ in Open Heart
- Vol. 5 (1) , e000705
Randomised trial of the comparison of drug-eluting stents in patients with diabetes: OCT DES trial
Background To date, there have been limited comparisons performed between everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in patients with diabetes mellitus (DM). The objectives of this study was to assess the use of second-generation drug-eluting stents in patients with DM, using optical coherence tomography (OCT) to compare the level of stent coverage of Boston Scientific Promus Element EES compared with Medtronic Resolute Integrity ZES.(Clinicaltrials.gov number NCT02060357). Methods This is a single-centre randomised blinded trials assessing two commercially available stents in 60 patients with diabetes (ZES: n=30, EES: n=30). Patients underwent intracoronary assessment at 6 months with OCT assessing stent coverage, malapposition, neointimal thickness and percentage of in-stent restenosis (ISR). Results Of the 60 patients randomised, 46 patients underwent OCT analysis. There was no difference in baseline characteristics between the two groups. Both Promus Element and Resolute Integrity had low rates of uncovered struts at 6 months with no significant difference between the two groups (2.44% vs 1.24%, respectively; P=0.17). Rates of malapposition struts (3.9% vs 2.5%, P=0.25) and percentage of luminal loss did not differ between stent types. In addition, there was no significant difference in major adverse cardiovascular events (P=0.24) between the stent types. Conclusions This study is the first randomised trial to evaluate OCT at 6 months for ZES and EES in patients with diabetes. Both stents showed comparable strut coverage at 6 months, with no difference in ISR rates at 6 months.
- 5 April 2018
- Published by BMJ in Open Heart
- Vol. 5 (1) , e000705
Open AccessRandomised trial of the comparison of drug-eluting stents in patients with diabetes: OCT DES trial
Background To date, there have been limited comparisons performed between everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in patients with diabetes mellitus (DM). The objectives of this study was to assess the use of second-generation drug-eluting stents in patients with DM, using optical coherence tomography (OCT) to compare the level of stent coverage of Boston Scientific Promus Element EES compared with Medtronic Resolute Integrity ZES.(Clinicaltrials.gov number NCT02060357). Methods This is a single-centre randomised blinded trials assessing two commercially available stents in 60 patients with diabetes (ZES: n=30, EES: n=30). Patients underwent intracoronary assessment at 6 months with OCT assessing stent coverage, malapposition, neointimal thickness and percentage of in-stent restenosis (ISR). Results Of the 60 patients randomised, 46 patients underwent OCT analysis. There was no difference in baseline characteristics between the two groups. Both Promus Element and Resolute Integrity had low rates of uncovered struts at 6 months with no significant difference between the two groups (2.44% vs 1.24%, respectively; P=0.17). Rates of malapposition struts (3.9% vs 2.5%, P=0.25) and percentage of luminal loss did not differ between stent types. In addition, there was no significant difference in major adverse cardiovascular events (P=0.24) between the stent types. Conclusions This study is the first randomised trial to evaluate OCT at 6 months for ZES and EES in patients with diabetes. Both stents showed comparable strut coverage at 6 months, with no difference in ISR rates at 6 months.